Prognostic value of plasma chitotriosidase activity in acute stroke patients

International Journal of Stroke

Volumn 9, Issue 7, 2014, Pages 910-916

  Bustamante, Alejandro ^a   Dominguez, Carmen ^a,b   Rodriguez Sureda, Víctor ^a,b   Vilches, Angel ^a,b   Penalba, Ana ^a   Giralt, Dolors ^a   García Berrocoso, Teresa ^a   Llombart, Victor ^a   Flores, Alan ^a   Rubiera, Marta ^a   Molina, Carlos ^a   Alvarez Sabín, José ^a   Montaner, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Biomarkers; Chitotriosidase; Inflammation; Ischemic stroke; Prognosis

Indexed keywords

CHITOTRIOSIDASE; TISSUE PLASMINOGEN ACTIVATOR; BETA N ACETYLHEXOSAMINIDASE; BIOLOGICAL MARKER;

AGED; ARTICLE; ASSESSMENT OF HUMANS; BIOASSAY; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; DISABILITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FLUOROMETRIC ASSAY; HUMAN; IN HOSPITAL MORTALITY; LONG TERM DISABILITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NERVOUS SYSTEM INFLAMMATION; NET RECLASSIFICATION IMPROVEMENT; NEUROLOGIC DISEASE; NEUROLOGICAL DETERIORATION; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; BLOOD; MULTIVARIATE ANALYSIS; STROKE; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; FEMALE; HEXOSAMINIDASES; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; STROKE; TREATMENT OUTCOME;

EID: 84907884646     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12160     Document Type: Article

References (27)

1. Roger VL, Go AS, Lloyd-Jones DM etal. Heart disease and stroke statistics - 2012 update: a report from the American heart association. Circulation 2012; 125:e2-e220.
2. Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation 2011; 124:314-323.
3. Koennecke HC, Belz W, Berfelde D etal. on behalf of the Berlin Stroke Register investigators. Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. Neurology 2011; 77:965-972.
4. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 2009; 40:380-389.
5. Montaner J, Molina CA, Monasterio J etal. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107:598-603.
6. Montaner J, Fernandez-Cadenas I, Molina CA etal. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 2006; 37:1205-1210.
7. Castillo J, Leira R. Predictors of deteriorating cerebral infarct: role of inflammatory mechanisms: would its early treatment be useful? Cerebrovasc Dis 2001; 11(Suppl. 1):40-48.
8. Hallenbeck JM. Inflammatory reactions at the blood-endothelial interface in acute stroke. Adv Neurol 1996; 71:281-297.
9. van Eijk M, van Roomen CP, Renkema GH etal. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol 2005; 17:1505-1512.
10. Bussink AP, van Eijk M, Renkema GH, Aerts JM, Boot RG. The biology of the Gaucher cell: the cradle of human chitinases. Int Rev Cytol 2006; 252:71-128.
11. Boot RG, Renkema GH, Verhoek M etal. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 1998; 273:25680-25685.
12. Karadag B, Kucur M, Isman FK, Hacibekiroglu M, Vural VA. Serum chitotriosidase activity in patients with coronary artery disease. Circ J 2008; 72:71-75.
13. Palasik W, Fiszer U, Lechowicz W, Czartoryska B, Krzesiewicz M, Lugowska A. Assessment of relations between clinical outcome of ischemic stroke and activity of inflammatory processes in the acute phase based on examination of selected parameters. Eur Neurol 2005; 53:188-193.
14. Sotgiu S, Barone R, Zanda B etal. Chitotriosidase in patients with acute ischemic stroke. Eur Neurol 2005; 54:149-153.
15. Adams HP Jr, Bendixen BH, Kappelle LJ etal. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24:35-41.
16. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337:1521-1526.
17. Brott TG, Haley EC Jr, Levy DE etal. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23:632-640.
18. Hollak CEM, van Weely S, van Oers MHJ, Aerts JMFG. Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease. J Clin Invest 1994; 93:1288-1292.
19. Comabella M, Domínguez C, Rio J etal. Plasma chitotriosidase activity in multiple sclerosis. Clin Immunol 2009; 131:216-222.
20. Canudas J, Cenarro A, Civeira F etal. Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid-lowering agents, atorvastatin and bezafibrate. Metabolism 2001; 50:447-450.
21. Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010; 48:1703-1711.
22. Whiteley W, Jackson C, Lewis S etal. Inflammatory markers and poor outcome alter stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med 2009; 6:e1000145.
23. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31:2325-2329.
24. Blanco M, Castellanos M, Rodríguez-Yáñez M etal. High blood pressure and inflammation are associated with poor prognosis in lacunar infarctions. Cerebrovasc Dis 2006; 22:123-129.
25. Rallidis LS, Vikelis M, Panagiotakos DB etal. Inflammatory markers and in-hospital mortality in acute ischaemic stroke. Atherosclerosis 2006; 189:193-197.
26. Whiteley W, Wardlaw J, Dennis M etal. The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 2012; 43:86-91.
27. Montaner J, García-Berrocoso T, Mendioroz M etal. Brain natriuretic peptide is associated with worsening and mortality in acute stroke patients but adds no prognostic value to clinical predictors of outcome. Cerebrovasc Dis 2012; 34:240-245.